Haloperidol treatment downregulates DCC expression in the ventral tegmental area

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Biology

Background:

• Schizophrenia involves abnormal mesocorticolimbic dopamine (DA) circuitry.
• Deleted in Colorectal Cancer (DCC), a netrin-1 receptor, influences DA circuitry development and plasticity.
• Amphetamine exposure increases DCC in the VTA, enhancing DA sensitization.

Purpose of the Study:

• To investigate if typical and atypical antipsychotics regulate DCC expression.
• To explore the role of DCC in antipsychotic treatment mechanisms.

Main Methods:

• Adult mice received haloperidol, clozapine, or risperidone for 4 weeks.
• DCC levels were quantified in brain regions (VTA, PFC, NAc, Striatum) using Western blot.
• UNC-5 homologue levels were also assessed to confirm DCC specificity.

Main Results:

• Haloperidol significantly decreased DCC levels (~50%) in the VTA, but not in DA terminal regions.
• Neither clozapine nor risperidone altered DCC expression.
• Haloperidol did not affect UNC-5 homologue levels, indicating specific targeting of DCC signaling.

Conclusions:

• Typical antipsychotics, exemplified by haloperidol, selectively downregulate DCC in the VTA.
• This suggests that typical antipsychotics may induce functional reorganization in the VTA via DCC-mediated netrin-1 signaling, contributing to schizophrenia symptom management.